Table 3.
Changes in T cell subpopulations in NSCLC patients after different anti-cancer therapies.
| T cell subpopulations | Immunotherapy | Chemotherapy | Immuno-chemotherapy | Adjuvant chemotherapy | Antibodies against VEGF |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| before | after | q-value | before | after | q-value | before | after | q-value | before | after | q-value | before | after | q-value | |
| T cells (cells/µL) | 575.7 | 952.6 | 0.896 | 631.7 | 1099.1 | 0.839 | 946.1 | 811.1 | 0.548 | 983.2 | 1131.4 | 0.673 | 869 | 1530 | 0.841 |
| T helper cells (cells/µL) | 336.3 | 546.0 | 0.985 | 429.0 | 758.7 | 0.981 | 652.7 | 577.8 | 0.503 | 628.6 | 706.0 | 0.646 | 583 | 954 | 0.749 |
| Cytotoxic T cells (cells/µL) | 173.3 | 334.9 | 0.743 | 158.1 | 266.7 | 0.882 | 219.7 | 194.4 | 0.618 | 268.8 | 352.4 | 0.566 | 242 | 504 | 0.789 |
| T cells % of lymphocytes+A86 | 63.9 | 72.9 | 0.057 | 67.9 | 69.4 | 0.588 | 73.4 | 72.8 | 0.994 | 71.0 | 66.8 | 0.605 | 79 | 85 | 0.934 |
| T helper cells % of T cells | 37.1 | 43.7 | 0.111 | 45.3 | 40.3 | 0.814 | 51.1 | 51.4 | 0.590 | 45.0 | 41.8 | 0.708 | 53 | 53 | 0.907 |
| Cytotoxic T cells % of T cells | 21.7 | 24.0 | 0.848 | 17.9 | 23.3 | 0.588 | 16.9 | 17.8 | 0.080 | 19.8 | 20.6 | 0.781 | 22 | 28 | 0.732 |
| CD4/CD8 ratio | 2.4 | 2.6 | 0.487 | 3.6 | 2.5 | 0.897 | 3.8 | 3.3 | 0.159 | 2.3 | 2.1 | 0.877 | 2.4 | 1.9 | 0.749 |
| Double negative T cells (CD4-CD8-) % of T cells | 6.2 | 4.9 | 0.920 | 2.1 | 4.0 | 0.986 | 5.3 | 4.2 | 0.318 | 5.5 | 4.6 | 0.697 | 4.7 | 3.6 | 0.907 |
| Double positive T cells (CD4+CD8+) % of T cells | 0.7 | 1.6 | 0.729 | 4.0 | 3.7 | 0.839 | 1.1 | 1.2 | 0.953 | 2.2 | 1.7 | 0.781 | 0.9 | 1.2 | 0.856 |
| Activated T-helper cells (CD38+) % of T-helper cells | 53.7 | 50.4 | 0.987 | 41.6 | 44.9 | 0.839 | 66.1 | 68.4 | 0.326 | 44.0 | 47.0 | 0.784 | 46 | 46 | 0.732 |
| Activated T-helper cells (HLA-DR+) % of T-helper cells | 15.9 | 15.4 | 0.431 | 10.7 | 16.1 | 0.893 | 8.6 | 9.9 | 0.807 | 15.8 | 10.6 | 0.566 | 11 | 7 | 0.856 |
| Activated T helper cells (HLA-DR+CD38+) % of T helper cells | 9.3 | 7.4 | 0.525 | 4.1 | 9.9 | 0.588 | 4.0 | 6.5 | 0.330 | 6.6 | 5.8 | 0.903 | 4 | 3 | 0.907 |
| Activated cytotoxic T cells (CD8/CD38) % of cytotoxic T cells | 44.4 | 57.4 | 0.050 | 32.4 | 38.0 | 0.588 | 34.9 | 51.3 | 0.000 | 31.8 | 40.2 | 0.546 | 36 | 49 | 0.856 |
| Activated cytotoxic T cells (HLA-DR+) % of cytotoxic T cells | 26.9 | 38.1 | 0.031 | 19.1 | 35.4 | 0.588 | 14.7 | 19.5 | 0.030 | 37.6 | 42.2 | 0.566 | 40 | 52 | 0.732 |
| Activated cytotoxic (HLA-DR+CD38+) T cells % of cytotoxic T cells | 17.7 | 29.7 | 0.031 | 10.1 | 23.7 | 0.588 | 7.6 | 14.4 | 0.002 | 18.8 | 26.8 | 0.334 | 13 | 32 | 0.732 |
Values “before” and “after” correspond to the measured values before the initial treatment and the measured value after the last treatment, respectively, after an average observation time of 718/459/473/1,060/1,462 days of immunotherapy/chemotherapy/immunochemotherapy/adjuvant chemotherapy/antibodies against VEGF. Q-values correspond to the significance of the estimated change over time from linear mixed modelling. VEGF, Vascular endothelial growth factors; HLA-DR, Human Leukocyte Antigen-DR isotype.